Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jun;133(6):726.
doi: 10.1001/jamaophthalmol.2015.0502.

Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials

Gui-shuang Ying  1 , Maureen G Maguire  1
Affiliations
Comment

Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials

Gui-shuang Ying et al. JAMA Ophthalmol. 2015 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ying reported having received a consulting fee from Janssen Research and Development LLC outside this work. No other disclosures were reported.

Comment on

References

    1. Messori A. Comparative effectiveness of bevacizumab and ranibizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. doi: 10.1001/jamaophthalmol.2014.4642. [published online November 27, 2014] - DOI - PubMed
    1. Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. - PMC - PubMed
    1. Ying GS, Kim BJ, Maguire MG, et al. CATT Research Group Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol. 2014;132(8):915–921. - PMC - PubMed

MeSH terms

Substances